Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore

Introduction: Ustekinumab is a human monoclonal antibody that binds to the p40 subunit of both interleukin (IL)-12 and IL-23, and it is approved for the treatment of moderate to severe plaque psoriasis. In this study, we assessed the efficacy and safety of patients receiving ustekinumab for psoriasi...

Full description

Saved in:
Bibliographic Details
Main Authors: Wai Sze Agnes Chan, Yisheng Wong, Hazel Hwee Boon Oon, Colin Thiam Seng Theng, Wei-Sheng Chong
Format: Article
Language:English
Published: Wolters Kluwer – Medknow Publications 2023-07-01
Series:Singapore Medical Journal
Subjects:
biologic
psoriasis
ustekinumab
Online Access:https://journals.lww.com/10.11622/smedj.2022029
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items